CUV — Clinuvel Pharmaceuticals Balance Sheet
0.000.00%
- AU$618.02m
- AU$394.45m
- AU$95.02m
- 99
- 57
- 93
- 96
Annual balance sheet for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 82.7 | 122 | 157 | 184 | 224 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 16.1 | 16.2 | 22.2 | 26.2 | 27.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 103 | 141 | 190 | 222 | 263 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.6 | 2.7 | 2.85 | 7.72 | 7.13 |
| Net Goodwill | |||||
| Other Long Term Assets | |||||
| Total Assets | 109 | 144 | 194 | 231 | 272 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.71 | 13.7 | 25.5 | 25.2 | 27.2 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.83 | 18.4 | 29.1 | 28.1 | 30.9 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 98.7 | 126 | 165 | 203 | 241 |
| Total Liabilities & Shareholders' Equity | 109 | 144 | 194 | 231 | 272 |
| Total Common Shares Outstanding |